News

All Articles

Filter by year:

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

November 18, 2024

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

November 18, 2024

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

October 18, 2024

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

October 14, 2024

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

September 30, 2024

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

August 16, 2024

Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results

August 12, 2024

Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024

August 6, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke

June 17, 2024

Helius Medical Technologies, Inc. Announces Third-Party Reimbursement for PoNS® from Major Insurance Carrier

May 29, 2024

Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS

May 23, 2024

Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

May 20, 2024

Helius Medical Technologies, Inc. Reports First Quarter 2024 Financial Results

May 13, 2024

Helius Medical Technologies, Inc. to Release First Quarter 2024 Financial Results on May 13, 2024

May 10, 2024

Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering

May 6, 2024

Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)

May 6, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

April 24, 2024

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™

April 3, 2024

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

March 28, 2024

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

March 15, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

March 12, 2024

Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference

March 7, 2024

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

March 4, 2024

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

February 6, 2024

Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists’ Ability to Customize PoNS Therapy® to Improve Gait in People with MS

February 5, 2024

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

January 11, 2024

Helius Medical Technologies to Present at NobleCon19 Annual Conference

November 30, 2023

Helius Medical Technologies, Inc. Reports Third Quarter 2023 Financial Results

November 9, 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy™ Helps Patients with Traumatic Brain Injury Return to Work

November 6, 2023

Helius Medical Technologies, Inc. to Release Third Quarter 2023 Financial Results on November 9, 2023; Announces Extended Cash Runway into Q2 2024

November 2, 2023

Pacific Blue Cross and HealthTech Connex report successful results in brain injury rehabilitation project

November 2, 2023

Helius Medical Technologies, Inc. Receives Letter of Intent from the Québec Ministry of Health and Social Services to Purchase 30 PoNS® Devices

October 12, 2023

Helius Medical Technologies to Participate at Two Upcoming Healthcare Conferences

October 2, 2023

Helius Medical Technologies, Inc. Receives UPC Numbers for its PoNS® System and Mouthpiece

September 28, 2023

Helius to Bring its Innovative PoNS Therapy for Improvement of Gait in People with MS, to the 2023 Academy of Neurologic Physical Therapy Conference

September 21, 2023

University of Montreal’s School of Rehabilitation to Purchase Ten PoNS® Devices for Research Study on Stroke Recovery

September 20, 2023

Helius Medical Technologies to Present at the 2023 Interdisciplinary Association of Functional Neuroscience and Rehabilitation Conference

September 13, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

September 5, 2023

Helius Medical Technologies Announces Reverse Stock Split

August 16, 2023

Helius Medical Technologies, Inc. Reports Second Quarter 2023 Financial Results

August 10, 2023

Helius Medical Technologies, Inc. Announces Participation of Montefiore Medical Center in its PoNS® Therapeutic Experience Program

August 7, 2023

Helius Medical Technologies, Inc. to Release Second Quarter 2023 Financial Results on August 10, 2023

August 2, 2023

Helius Medical Technologies, Inc. Expands Stroke Trial at the Medical University of South Carolina

July 27, 2023

Helius Medical Technologies Announces DMEPOS Accreditation for PoNS

June 20, 2023

Helius Medical Technologies to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest

June 14, 2023

Helius Medical Technologies to Present at LD Micro Invitational XIII 2023

May 25, 2023

Helius to Highlight Innovative PoNS Therapy™ at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

May 24, 2023

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2023

Helius Medical Technologies, Inc. Reports First Quarter 2023 Financial Results

May 11, 2023

Helius Medical Technologies, Inc. to Release First Quarter 2023 Financial Results on May 11, 2023

May 4, 2023

Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

April 17, 2023

Helius Medical Technologies, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Class A Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary

March 23, 2023

Helius Medical Technologies and HealthTech Connex Announce Exclusive Distribution Agreement for the Portable Neuromodulation Stimulator (PoNS®) Device

March 22, 2023

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023

Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

March 9, 2023

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

March 6, 2023

Helius Medical Technologies to Present at the 35th Annual ROTH Conference

March 2, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

February 15, 2023

Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

January 23, 2023

Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023

January 19, 2023

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

January 10, 2023

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

January 5, 2023

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

January 3, 2023

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

December 30, 2022

Helius Medical Technologies, Inc. Reports Third Quarter 2022 Financial Results

November 14, 2022

Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer and MGH Institute of Health Professions to its Therapeutic Experience Program

November 9, 2022

Helius Medical Technologies, Inc. Announces Participation of Oregon Health & Science University in its Therapeutic Experience Program

November 8, 2022

Helius to Showcase Innovative PoNS Device at ACRM’s 2022 Conference – Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

November 3, 2022

Helius Medical Technologies, Inc. to Release Third Quarter 2022 Financial Results on November 14, 2022

November 1, 2022

Helius Salutes Physical Therapists for Their Role in Helping People with MS Improve Their Gait

October 13, 2022

Helius Medical Technologies to Present at the ROTH Capital Partners Inaugural Healthcare Opportunities Conference

September 29, 2022

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

September 14, 2022

Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September

September 6, 2022

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 17, 2022

Helius Medical Technologies, Inc. Reports Second Quarter 2022 Financial Results

August 15, 2022

Helius Medical Technologies, Inc. to Release Second Quarter 2022 Financial Results on August 15, 2022

August 10, 2022

Helius Medical Technologies, Inc. Announces Pricing of $18 Million Public Offering

August 5, 2022

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™

July 12, 2022

Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meetin

June 6, 2022

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

June 1, 2022

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

May 31, 2022

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 24, 2022

Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeutic Experience Program

May 17, 2022

Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial Launch of PoNS®

May 12, 2022

Helius Medical Technologies, Inc. to Release First Quarter 2022 Financial Results on May 12, 2022

May 3, 2022

Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®

April 27, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

April 26, 2022

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

March 14, 2022

Helius Medical Technologies, Inc. Provides Corporate Update

January 26, 2022

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2021

Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

December 17, 2021

Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®

December 14, 2021

Helius Medical Technologies, Inc.’s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Conference on December 9

December 6, 2021

Helius Medical Technologies, Inc. to Participate in 1x1 Meetings at 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021

November 15, 2021

Helius Medical Technologies, Inc. Announces Closing of $11.1 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

November 12, 2021

Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering of Common Stock

November 10, 2021

Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results

November 10, 2021

Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock

November 9, 2021

Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site

November 8, 2021

Helius Medical Technologies, Inc. Receives PoNS® Market Authorization in Australia

November 4, 2021